Genomics & Screening Core Facility

By integrating state-of-the-art equipment and technical expertise, the NUI Galway Genomics & Screening Core Facility has been established in Biomedical Sciences to provide a central resource for academic and industrial research groups looking to quickly expand and advance their current research.
Automated high-throughput and high-content discovery tools enable conventional cell-based biological reporter assays to systematically test large numbers of compounds, extracts or genes in a faster, more reliable and less expensive way than is possible manually, while providing a platform for novel assay development to interrogate model systems in new ways.
The Core also facilitates the characterisation of gene and protein functions and interactions through access to cutting edge single cell analysis tools, multiplexing instruments for biochemical assays, and a range of qPCR systems.
Drug Discovery & Characterisation
High Content Imaging
Cell-based assays
Enzyme-based assays
Environmental Sample Analysis
Single Cell Analysis
Quantitative Real-Time PCR (qPCR) 


InDrop Single Cell Analysis System
Chemical Compound Libraries
BigNeat Compund Storage Cabinet
Class II Biosafety Cabinet


Automated Assays Developed and In Development

Cell Viability (Resazurin, Hoechst, Sulforhodamine B and MTT assays)
High Content Immunofluorescent Centrosome Amplification analysis
In-Cell Western Protein analysis
Cytokine analysis (ELISA assays)
Biomaterials analysis
Immune Response (Flow Cytometry)
Stem Cell analysis (Alkaline Phosphotase and Calcium assays)
Genotoxicity analysis (Ames and Clastogenicity assays
Quantitative RT-PCR setup
Case Studies

Post-traumatic immunosuppression is reversed by anti-coagulated salvaged blood transfusion: deductions from studying immune status after knee arthroplasty. Islam N, Whitehouse M, Mehendale S, Hall M, Tierney J, O'Connell E, Blom A, Bannister G, Hinde J, Ceredig R, Bradley BA. Clin Exp Immunol. 2014 Aug;177(2):509-20. doi: 10.1111/cei.12351. PubMed PMID: 24749651.

Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues. Monaghan D, O'Connell E, Cruickshank FL, O'Sullivan B, Giles FJ, Hulme AN, Fearnhead HO. Biochem Biophys Res Commun. 2014 Jan 10;443(2):761-7. doi: 10.1016/j.bbrc.2013.12.041. Epub 2013 Dec 12. PubMed PMID: 24333448.
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. FitzGerald J, Murillo LS, O'Brien G, O'Connell E, O'Connor A, Wu K, Wang GN, Rainey MD, Natoni A, Healy S, O'Dwyer M, Santocanale C. PLoS One. 2014 Jun 5;9(6):e98891. doi: 10.1371/journal.pone.0098891. eCollection 2014. PubMed PMID: 24902048; PubMed Central PMCID: PMC4047068.

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Toner AP, McLaughlin F, Giles FJ, Sullivan FJ, O'Connell E, Carleton LA, Breen L, Dunne G, Gorman AM, Lewis JD, Glynn SA. Br J Cancer. 2013 Oct 15;109(8):2131-41. doi: 10.1038/bjc.2013.537. Epub 2013 Sep 19. PubMed PMID: 24052043; PubMed Central PMCID: PMC3798953.
Useful Links Contact Information
Dr. Enda O'Connell
Screening Core Facility Manager
Telephone: +353 91 495435
Screening Core Director
Lecturer in Pharmacology and Therapeutics
Principal Investigator in the Apoptosis Research Centre
Telephone: +353 91 495240